About
Technology
Issues
FAQ
Links
Official Page
1099MO Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)
site/software ©
exaly
; All materials licenced under
CC by-SA
.